Clinical Trial Update: Abituzumab in SSc-ILD [Phase 2]

View source ↗

Summary

Phase 2 trial of abituzumab in systemic sclerosis-associated interstitial lung disease was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis-associated Interstitial Lung Disease

Drugs mentioned

• abituzumab (abituzumab)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Systemic Sclerosis-associated Interstitial Lung Disease | Phase 2 | Status: TERMINATED | Results posted: 2019-06-18